Sign in

NCT07585773Not yet recruiting

Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)

A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Renal Function in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism

Source: ClinicalTrials.gov · Last updated 18 May 2026

Brief summary (registry, in English)

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether laparoscopic splenectomy can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
30 (estimated)
First submitted
22 Apr 2026
Start date
1 May 2026
Primary completion date
28 Feb 2029
Lead sponsor
Northern Jiangsu People's Hospital
NCT number
NCT07585773

What you commit to

  • Study type: Observational
  • Planned participants: 30
  • From 1 May 2026 to the primary completion date, 28 Feb 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous abdominal surgery precluding safe laparoscopic splenectomy
  • Cirrhotic complications (portal hypertension bleeding, hepatic encephalopathy, refractory ascites) within 1 month before surgery

Other illness

  • Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)
  • Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders

Other

  • Child-Pugh Class C liver cirrhosis
  • Pregnancy or lactation
  • Poor compliance, inability to complete follow-up

Who the study is looking for

  • Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
  • Splenomegaly and hypersplenism
  • No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )
  • Age 18-80 years, male or female
  • Child-Pugh Class A or B liver function
  • No history of primary renal disease or acute kidney injury (AKI)
  • Signed written informed consent
  • Ability to complete 24-month follow-up

Age in the registry: 18 years to 80 years · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Clinical Medical College of Yangzhou University
Coordinator of this site? Confirm its status
YangzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.